Error loading player: No playable sources found

5115

IBD Controlled Trials II

Date
May 21, 2024

SOCIETY: AGA This session is the second session of the ever-popular and clinically impactful clinical trials sessions in IBD. Insights into novel agents including obefazimod, VTX002. MH002, risankizumab, and mirikizumab will be presented.

Moderators

Speaker Image for Miguel Regueiro
Cleveland Clinic
Speaker Image for Hans Herfarth
UNC Chapel Hill

Related Products

Thumbnail for Uncontrolled Therapeutic Observations in IBD
Uncontrolled Therapeutic Observations in IBD
SOCIETY: AGA In this session, several clinically relevant presentations will put the attendee at the cutting edge of research and clinical care, with regard to stem cells for perinal fistulas, biologic de-escalation, subcutaneous biologics, and use of small molecules in microscopic colitis
Thumbnail for Role of the Environment in IBD
Role of the Environment in IBD
SOCIETY: AGA As our scientific tools improve, so does our ability to link the environment with different aspects of IBD…
Thumbnail for Novel Observations in IBD
Novel Observations in IBD
MONITORING IBD BY INTESTINAL ULTRASOUND DECREASES TIME TO TREATMENT CHANGE AND TIME TO REMISSION IN COMPARISON TO CONVENTIONAL MANAGEMENT: ANALYSIS OF PATIENTS WITH IBD ON MULTIPLE IBD THERAPIES